Chief Physician, Department of Thoracic Surgery, Peking University Cancer Hospital Specialties: Perioperative comprehensive treatment of NSCLC and radical lung cancer surgery following neoadjuvant therapy; extensive clinical experience and in-depth research in the full-course management of stage III–IV lung cancer, surgical treatment of complex mediastinal tumors, and precise surgical resection of pulmonary metastases. Standing Committee Member and Secretary-General, Lung Cancer Integrated Rehabilitation Committee, Chinese Anti-Cancer Association. Trained under Professor Chen Keneng, a renowned thoracic surgery expert in China, with long-term engagement in clinical diagnosis, treatment, and research of thoracic tumors, possessing extensive surgical experience and multidisciplinary management capabilities. Has conducted pioneering work in the integration of neoadjuvant immunotherapy, targeted therapy, and surgical strategies, and participated in multiple international multicenter clinical trials, including CheckMate 816, Keynote-671, and NeoAdaura, contributing to the standardization of neoadjuvant therapy for lung cancer in China. In research, focuses on the mechanisms, sensitivity prediction, and prognostic model development of perioperative treatment for thoracic tumors. In recent years, has published multiple papers in international oncology and thoracic surgery journals such as the *Journal of Clinical Oncology*, *Journal of Thoracic Oncology*, *Journal of Thoracic and Cardiovascular Surgery*, and *Annals of Thoracic Surgery*. Also participated in the National Key R&D Program project "Molecular Characteristics and Mechanisms of Neoadjuvant Immunotherapy in Lung Cancer," closely integrating basic research with clinical practice to advance precision treatment of thoracic tumors.